This is a multicentre, prospective, study of EGFR )Epidermal Growth Factor Receptor) mutation status in advanced NSCLC (Non-small cell lung cancer)patients (locally advanced and/or metastatic disease) with adenocarcinoma histology proposed to be conducted at 15 sites from different geographical regions across India. The study targets to enrol 268 patients over a period of 6 months.
Description: by tissue and plasma based testing in terms of Overall Concordance, Sensitivity, specificity, Positive predictive value & negative predictive value.
Measure: Determine the level of concordance between EGFR mutation status Time: 1 DayDescription: Frequency and percentage of TKI treatment naïve NSCLC patients with T790M mutation will be provided.
Measure: Assess the frequency of T790M mutation among study patients. Time: 1 DayCohort
There is one SNP
by tissue and plasma based testing in terms of Overall Concordance, Sensitivity, specificity, Positive predictive value & negative predictive value.. Assess the frequency of T790M mutation among study patients.. Frequency and percentage of TKI treatment naïve NSCLC patients with T790M mutation will be provided.. Inclusion Criteria: 1. Patients who provide written informed consent 2. Patients aged 18 years and older 3. Newly diagnosed patients with Metastatic (stage IV) NSCLC. --- T790M ---
by tissue and plasma based testing in terms of Overall Concordance, Sensitivity, specificity, Positive predictive value & negative predictive value.. Assess the frequency of T790M mutation among study patients.. Frequency and percentage of TKI treatment naïve NSCLC patients with T790M mutation will be provided.. Inclusion Criteria: 1. Patients who provide written informed consent 2. Patients aged 18 years and older 3. Newly diagnosed patients with Metastatic (stage IV) NSCLC. --- T790M --- --- T790M ---